一年关店118家的连锁药房巨头漱玉平民再度遭遇医保解约。近日，山东省医疗保障局的一纸公告显 示，济南两家漱玉平民药房被正式解除省直医保协议关系。 就在消息公布的前三天，漱玉平民大药房连锁股份有限公司（简称"漱玉平民"）创始人兼总裁秦光霞宣 布减持公司3%股份，套现约1.5亿元。这位与董事长李文杰并肩创业26年的元老，在公司遭遇上市首次 年度亏损之后选择减持，引发市场一片哗然。 就在漱玉平民遭遇上市以来首次年度亏损和医保频频解约的敏感时刻，创始人却选择高位套现，这家曾 经风光上市的医药零售巨头如今"屋漏偏逢连夜雨"，正面临着前所未有的生存和信任危机。 医保违规"常客" 漱玉平民作为一家知名连锁药房，在济南、青岛等地区拥有众多门店，此次山东省医保局解除协议的两 家漱玉平民门店未公布具体事由，对此记者致电漱玉平民，对方工作人员表示"不了解详情"。而记者致 电山东省医疗保障局被告知："如果自动选择解除医保协议的话会在通告中体现，如未标明则可能有不 便告知的原因。" "解除医保协议的原因主要可分为两类，一种是医保部门主动解除，一种是药店主动申请解除。如果是 医保部门主动解除原因可能为医保违规或重大信息变更未报备。"医药 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 2025 年 6 月 5 日，公司将部分上述用于暂时补充流动资金的募集资金 5,000.00 万元提 前归还至公司募集资金账户，使用期限未超过 12 个月。同时，公司已将上述募集资金的归 还情况通知了保荐机构及保荐代表人。 截至本公告披露日，公司尚未归还的募集资金金额为 17,000.00 万元，公司将在规定 期限内归还至募集资金专户，并及时履行信息披露义务。 特此公告。 漱玉平民大药房连锁股份有限公司 董 事 会 关于提前归还部分用于暂时补充流动资金的闲置募集资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2024 年 7 月 11 日召开第三 届董事会第三十三次会议和第三届监事会第二十二次会议，分别审议通过了《关于使用部 分闲置募集资金暂时补充流动资金的议案》，同意公司在不 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于调剂担保额度暨为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日召开第 四届董事会第三次会议，于 2025 年 2 月 6 日召开 2025 年第一次临时股东大会，审议通过 了《关于 2025 年度公司及子公司向银行等机构申请综合授信额度及提供担保的议案》，同 意公司及子公司 2025 年度对合并报表范围内各级子公司提供的担保额度为人民币 167,011.00 万元。公司可以根据实际情况，在上述额度范围内，在符合要求的担保对象之 间可以进行担保额度的调剂，担保额度调剂以不跨过资产负债率超过 70%的标准进行调剂。 担保额度有效期自 2025 年第一次临时股东大会审议通过之日起十二个月。具体内容详见公 司于 202 ...

Policy Developments - The National Medical Products Administration (NMPA) announced the conversion of Xiaoer Ganmao Ning Granules and Pugongying Granules from prescription to over-the-counter drugs [1] Drug Approvals - Eisai's lemborexant has been approved by the NMPA for sale in China, targeting adult insomnia, particularly difficulties in falling and maintaining sleep [2] - Rongchang Biologics' injectable Taitasip has received NMPA approval for a new indication to treat generalized myasthenia gravis (gMG) [3] Capital Markets - Chenglian Technology has successfully completed nearly 200 million RMB in B+ round financing, bringing its total financing to over 500 million RMB [4] - Xiantong Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CICC and CITIC Securities as joint sponsors [5] Industry Collaborations - Drug Ranch has reached an option agreement with Xiamen Tebao Biotech for clinical collaboration on the ALPK1 agonist DF-006 for hepatitis B and liver cancer in Greater China [6] - Chengdu Guowei Biopharmaceutical has signed a new drug research cooperation agreement with Xinlitai, granting exclusive rights for the AGT-siRNA drug GW906 in the Chinese market [8] Market Activity - Paige Biotech has officially listed on the Hong Kong Stock Exchange with an issue price of 15.6 HKD per share, corresponding to a market capitalization of approximately 6.02 billion HKD [7] - The innovative drug sector is experiencing increased activity, with companies actively pursuing technology or commercial rights to accelerate resource integration [9] Corporate Changes - Taiji Group announced the resignation of supervisor Xu Tingmei due to work reasons, which will not affect the normal operation of the supervisory board [10] - Shareholder Qin Guangxia of Shuyuping plans to reduce her stake by up to 3%, amounting to a maximum of 12.07 million shares [11] - Seer Medical announced the transfer of 51% equity in its subsidiary Akesu Yonglin, with part of the transfer payment of 4.2 million RMB still outstanding [12]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-045 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于持股 5%以上股东、董事、高级管理人员减持股份预披露的公告 公司持股 5%以上股东、董事、高级管理人员秦光霞女士保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示 1、漱玉平民大药房连锁股份有限公司（以下简称"公司"或"发行人"）持股 5%以上 股东、董事、高级管理人员秦光霞女士持有公司股份 73,440,000 股（占公司总股本比例为 18.25%），计划在本公告发布之日起 15 个交易日后的 3 个月内（即 2025 年 6 月 19 日至 2025 年 9 月 18 日），以集中竞价和/或大宗交易方式共计减持本公司股份不超过 12,070,918 股， 占公司总股本的 3%。 注：截至 2025 年 5 月 26 日，公司总股本为 405,352,766 股，扣除回购专户中 ...

北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2024 年年度股东大会的 法律意见 地址：山东省济南市高新区舜泰北路 567 号银丰科技公园 2 号楼 邮编：250102 网址：www.dehenglaw.com 电话：（86）531-8166 3606 北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2024 年年度股东大会的法律意见 北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2024 年年度股东大会的 法律意见 德恒 11G20230145-12 号 致：漱玉平民大药房连锁股份有限公司 北京德恒（济南）律师事务所（以下简称"本所"）作为漱玉平民大药房连 锁股份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派张璐 律师、赵程程律师（以下简称"本所律师"）出席公司 2024 年年度股东大会（以 下简称"本次股东大会"），依据《中华人民共和国公司法》（以下简称《公司 法》）、《上市公司股东大会规则》（以下简称《股东大会规则》）等现行有效 的法律、法规、规范性文件以及《漱玉平民大药房连锁股份有限公司章程》（以 下简称《公司章程》）、《漱玉平民大药 ...

| | | 漱玉平民大药房连锁股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会不存在变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 （1）会议召开时间、地点及召开方式 漱玉平民大药房连锁股份有限公司（以下简称"公司"）2024 年年度股东大会于 2025 年 5 月 20 日下午 2:30 在山东省济南市历城区山大北路 56 号公司会议室以现场表决和网络 投票相结合的方式召开。通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 20 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统进行投 票的具体时间为 2025 年 5 月 20 日 9:15-15:00 的任意时间。 （2）会议召集人：公司董事会 （3）会议主持人：李文杰 （4）本次会议的召集、召开与表决程序符合《公司法》和《公司章程》的规定。 2、会议出席情况 （1）股东出席的总体情况： ...

Financial Performance - In 2024, the company achieved a total revenue of 9.57 billion CNY, representing a year-on-year growth of 4.13% [2] - The net profit attributable to shareholders was -189 million CNY, a significant decline of 241.90% compared to the previous year [2] - In Q1 2025, the company reported a revenue of 2.379 billion CNY, a decrease of 2.48% year-on-year, with a net profit of 25.6239 million CNY, marking a growth of 143.85% compared to the same period last year [3] Shareholder Information - As of April 30, 2025, the total number of shareholders is 13,133 [4] Growth Strategies - Future profit growth will focus on: - Expansion of store networks through self-built, mergers, franchises, and alliances [4] - Digital transformation and new retail strategies to enhance operational efficiency and online penetration [4] - Development of proprietary brands and diversification of product lines, including health products targeting younger demographics [4] - Optimization of logistics and supply chain systems to support franchise expansion and improve procurement cost structure [4] Industry Outlook - The pharmaceutical retail industry is expected to maintain steady growth due to structural adjustments and strategic opportunities driven by factors such as an aging population and increased health awareness [5] Acquisition Status - The company has terminated the acquisition of Tian Shili, as approved by the board on December 28, 2023 [6]

Group 1: Digital Innovation - The company is accelerating its transformation towards "smart pharmaceutical retail" through self-developed digital tools such as PDA, salary calculator, smart store inspection system, and "Yujian" intelligent recommendation system, enhancing service efficiency and customer experience [2] - In the supply chain, the company is optimizing inventory management using algorithm models and digital tools to reduce manual operations and speed up inventory turnover [2] - The company has launched the "Shuyuzhiyuan" risk control platform, utilizing big data models to comprehensively prevent operational risks [2] Group 2: Diversification and Product Development - The company is collaborating with Dashi and Wangwang to establish the "Dashi Shuyuyuan" pharmacy, which will offer a diverse range of products beyond pharmaceuticals, including OTC health products, baby formula, maternal and infant products, nutritional supplements, medical devices, and cross-border products [3] - In 2024, the company's self-owned product sales achieved a year-on-year growth of 9%, accounting for over 13% of total retail sales [3] Group 3: Financial Performance and Store Distribution - The company's asset-liability ratio is slightly higher than the industry average due to its short listing time and small scale of equity financing, with recent market expansion through acquisitions [3] - As of March 2025, the company operates a total of 8,916 stores across Shandong, Liaoning, Heilongjiang, Fujian, Henan, and Gansu provinces, including 4,353 direct-operated stores and 4,563 franchised stores [3]

Core Points - The company reported a total operating revenue of 9.57 billion yuan for 2024, representing a year-on-year increase of 4.13% [1][2] - The net profit attributable to shareholders was -189 million yuan, a significant decline from a profit of 133 million yuan in the previous year, marking a decrease of 241.90% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -198 million yuan, compared to a profit of 127 million yuan in the previous year, reflecting a decrease of 255.99% [1][2] - The net cash flow from operating activities was 489 million yuan, an increase of 242.40% compared to the previous year [1][2] Financial Performance - For the first quarter of 2025, the company reported total operating revenue of 2.38 billion yuan, a decline of 2.48% year-on-year [3] - The net profit attributable to shareholders for the first quarter was 25.62 million yuan, a year-on-year increase of 143.85% [3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 23.26 million yuan, up 144.60% from the previous year [3] - The net cash flow from operating activities for the first quarter was 88.36 million yuan, an increase of 17.52% compared to the same period last year [3] Capital Raising - The company raised a total of 359.18 million yuan from its initial public offering, with a net amount of 299.37 million yuan after deducting issuance costs [4] - The final net amount raised was 26.05 million yuan less than the original plan of 559.87 million yuan [4] - The company has raised a total of 1.16 billion yuan since its listing [6]